News

Sublingual cyclobenzaprine (Tonmya), a nonopioid treatment for adults with fibromyalgia, targets nonrestorative sleep, a root ...
This approval brings the total to 4 of medications approved to treat fibromyalgia; in addition to cyclobenzaprine HCl ...
The U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine hydrochloride) sublingual tablets for the ...
Tonix said the product is the first to be approved specifically for fibromyalgia in more than 15 years. The antidepressant ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals Holding Corp.’s (NASDAQ:TNXP) Tonmya ...
Following decades of limited treatment options, people living with fibromyalgia will soon have access to a novel therapy ...
The FDA has approved Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of fibromyalgia in adults.
Pharmaceutical Technology on MSN8d

FDA approves Tonix’s Tonmya to treat fibromyalgia

Tonix Pharmaceuticals CEO Seth Lederman stated: “The FDA approval of Tonmya as a first-line treatment for fibromyalgia ...
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S.
A sublingual tablet form of the muscle relaxant cyclobenzaprine hydrochloride failed to achieve statistical significance in reducing fibromyalgia pain vs. placebo in a phase 3 trial, according to ...
FLEXERIL 5 mg, approved by the U.S. Food & Drug Administration in February 2003, is comparable in efficacy to the 10 mg strength, but has been shown to be less sedating.
The FDA has approved first-time generic formulations for cyclobenzaprine HCl 5-mg tablets (Flexeril), clopidogrel bisulfate 75-mg tablets (Plavix), and testosterone 1% gel (AndroGel).